A phase I, open-label, single-dose, mass balance study to investigate the absorption, distribution, metabolism, and excretion of COMP360 [14C]-psilocybin in healthy male participants
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Psilocybin (Primary)
- Indications Anorexia nervosa; Bipolar depression; Depressive disorders; Major depressive disorder; Pervasive child development disorders; Post-traumatic stress disorders; Somatoform disorders
- Focus Pharmacokinetics
- Sponsors COMPASS Pathways
- 20 Sep 2024 New trial record